Incidence of angioedema associated with angiotensin-converting enzyme inhibitors (ACE-I) has been estimated at 0.1%-2.2% of patients receiving treatment. Despite the potential severity of this disease state, standardized treatment is lacking. Traditional pharmacotherapy options include medications that target inflammatory mediators and the angiotensin pathway. However, because ACE-I-induced angioedema is caused by accumulation of bradykinin, these medications fail to target the underlying pathophysiology. Recently, novel therapies that target the kallikrein-bradykinin pathway have been studied. These include icatibant, ecallantide, C1 esterase inhibitors, and fresh-frozen plasma. Recent randomized controlled trials exhibit contradictory results with the use of icatibant. This is a focused review on traditional and novel treatment strategies for ACE-I-induced angioedema.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/TME.0000000000000211 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction and prevention of ACE-inhibitor-induced angioedema-an unmet clinical need in management of hypertension.
Hypertens Res
February 2024
Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
Lisinopril-Induced Small Bowel Angioedema: An Unusual Cause of Severe Abdominal Pain.
Am J Case Rep
November 2022
Department of Hospital Internal Medicine, Mayo Clinic, Phoenix, AZ, USA.
BACKGROUND Angiotensin-converting enzyme inhibitors (ACE-I) are one of the most frequently prescribed classes of medications with the rare adverse effect of angioedema, and isolated small bowel angioedema is a small subset of these cases. Isolated angioedema of the small bowel is a rare adverse effect of this commonly prescribed medication, and it mimics, symptomatically and radiographically, several other illnesses and is often misdiagnosed. While ACE-I are thought to be safe, the risk of angioedema is approximately 0.
View Article and Find Full Text PDFClinical Practice Statement: What is the Emergency Department Management of Patients with Angioedema Secondary to an ACE-Inhibitor?
J Emerg Med
July 2021
University of California at San Diego Medical Center, San Diego, California.
Background: Angioedema is a complication that has been reported in up to 1.0% of individuals taking angiotensin-converting enzyme inhibitors (ACE-Is). Importantly, the onset of angioedema can occur anywhere from hours to several years after initiation of therapy with ACE-Is.
View Article and Find Full Text PDFImaging Review of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema of the Head and Neck.
Cureus
March 2021
Neuroradiology, University of Florida Health, Jacksonville, USA.
Angiotensin-converting enzyme inhibitors (ACE-i) are commonly used medications to treat hypertension and congestive heart failure. Angioedema is a well-established side effect of ACE-i and most commonly manifests as swelling of the mucosal and extra-mucosal soft tissues in the head and neck. CT with contrast is generally used to evaluate for airway compromise and to exclude other etiologies of edema.
View Article and Find Full Text PDFTreatment of Life-Threatening ACE-Inhibitor-Induced Angioedema.
Adv Emerg Nurs J
June 2019
Department of Pharmacy, Loyola University Medical Center, Maywood, Illinois (Drs Hirschy, Shah, and Rech); and Department of Pharmacy, Novant Health-Forsyth Medical Center, Winston-Salem, North Carolina (Dr Davis).
Incidence of angioedema associated with angiotensin-converting enzyme inhibitors (ACE-I) has been estimated at 0.1%-2.2% of patients receiving treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!